GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zenith Capital Corp (OTCPK:ZHCLF) » Definitions » Other Current Receivables

Zenith Capital (Zenith Capital) Other Current Receivables : $0.00 Mil (As of . 20)


View and export this data going back to 2020. Start your Free Trial

What is Zenith Capital Other Current Receivables?

Zenith Capital's Other Current Receivables for the quarter that ended in . 20 was $0.00 Mil.


Zenith Capital Other Current Receivables Historical Data

The historical data trend for Zenith Capital's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zenith Capital Other Current Receivables Chart

Zenith Capital Annual Data
Trend
Other Current Receivables

Zenith Capital Quarterly Data
Other Current Receivables

Zenith Capital Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.


Zenith Capital Other Current Receivables Related Terms

Thank you for viewing the detailed overview of Zenith Capital's Other Current Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Zenith Capital (Zenith Capital) Business Description

Traded in Other Exchanges
N/A
Address
300, 4820 RIchard Road SW, Calgary, AB, CAN, T3E 6L1
Website
Zenith Capital Corp is a biotechnology investment company. The company operates through its wholly-owned subsidiary Zenith Epigenetics Ltd. It is a clinical-stage biotechnology company focused on discovering and developing novel therapeutics. The company is developing various novel combinations of BET inhibitors with other targeted agents. Its lead compound, ZEN-3694, is in clinical development for metastatic Castration Resistant Prostate Cancer (mCRPC) in collaboration with Astellas and Newsoara and in metastatic triple-negative breast cancer.

Zenith Capital (Zenith Capital) Headlines

No Headlines